Sleep disturbance after cessation of cannabis administration in mice
Cannabis withdrawal syndrome (CWS) in humans is characterized by various somatic symptoms, including sleep disturbances. In the present study, we investigated sleep alterations in mice after the cessation of arachidonylcyclopropylamide (ACPA), a cannabinoid type 1 receptor agonist, administration. A...
Gespeichert in:
Veröffentlicht in: | Neuropsychopharmacology Reports 2023-12, Vol.43 (4), p.505-512 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Cannabis withdrawal syndrome (CWS) in humans is characterized by various somatic symptoms, including sleep disturbances. In the present study, we investigated sleep alterations in mice after the cessation of arachidonylcyclopropylamide (ACPA), a cannabinoid type 1 receptor agonist, administration. ACPA‐administered mice (ACPA mice) displayed an increased number of rearings after the cessation of ACPA administration compared to saline‐administered mice (Saline mice). Moreover, the number of rubbings was also decreased in ACPA mice compared with those of the control mice. Electroencephalography (EEG) and electromyography (EMG) were measured for 3 days after the cessation of ACPA administration. During ACPA administration, there was no difference in the relative amounts of total sleep and wake time between ACPA and Saline mice. However, ACPA‐induced withdrawal decreased total sleep time during the light period in ACPA mice after ACPA cessation. These results suggest that ACPA cessation induces sleep disturbances in the mouse model of CWS.
Cessation of arachidonylcyclopropylamide (ACPA)induces somatic symptoms and sleep disturbance, a CB1 receptor agonist, to mice, Although ACPA itself does not affect them. |
---|---|
ISSN: | 2574-173X 2574-173X |
DOI: | 10.1002/npr2.12329 |